AstraZeneca’s Evusheld Wins EU Marketing Nod For Preventing COVID-19
If Approved Evusheld Will Become The EU’s Eighth COVID-19 Treatment
Executive Summary
The European Commission is expected to make a “rapid decision” on the European Medicines Agency’s recommendation today that Evusheld should be approved.
You may also be interested in...
Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval
The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.
Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls
The EMA is poised to say whether or not six new drugs are on track for pan-EU approval, including Janssen’s first cell therapy and an antibody combination to prevent COVID-19 in people with poor immune response.
ERC Not Giving Up On Glioma Immunotherapy In EU
ERC Belgium has pledged to collect more data to convince the European Medicines Agency that Sitoiganap merits approval. Meanwhile, UGA Biopharma said it would address the agency’s objections over its biosimilar version of eptacog alfa.